Back to results
US 2026/0297026 A1Published application
Usp30 inhibitors and uses thereof
AssigneeVincere Biosciences, Inc.
InventorsDonna L. Romero, Michael Garrett Johnson, Andrew David Lee, Bahareh Behrouz, Edward Lawrence Fritzen, JR.
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
Claims24
A compound of formula I′:
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- L1 is
- each R is independently hydrogen or a C1-3 aliphatic group;
- R1 is a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- each R2 is independently halogen, —CF3, —CN, —C(O)NHR, —NO2, —NHR, —NHC(O)R, —NHS(O)2R, —N(R)2, —OR, or a C1-6 aliphatic group;
- L2 is —C(O)N(R′)—;
- R′ is hydrogen or a C1-3 aliphatic group;
- L3 is —C(O)N(R″)—;
- R″ is hydrogen or a C1-3 aliphatic group;
- R3 is hydrogen or C1-3 aliphatic;
- R4 is hydrogen or C1-3 aliphatic;
- R5 is hydrogen or C1-3 aliphatic;
- Ring B is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each R6 is independently halogen, —CN, —NO2, —NHR, —N(R)2, —OR, or a C1-6 aliphatic group;
- Ring C is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each R7 is independently halogen, —CN, —NO2, —NHR, —N(R)2, —OR, or a C1-6 aliphatic group;
- each of m, n, and p is independently 0, 1, 2, 3 or 4.
15 more elements
A compound selected from the following or a pharmaceutically acceptable salt thereof:
Dependencies are inferred from the claim text.